Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
752 hedge funds and large institutions have $31.3B invested in Alexion Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 83 funds opening new positions, 244 increasing their positions, 313 reducing their positions, and 149 closing their positions.
52% more funds holding in top 10
Funds holding in top 10: 46 → 70 (+24)
0% less capital invested
Capital invested by funds: $31.3B → $31.3B (-$29.8M)
9% less funds holding
Funds holding: 824 → 752 (-72)
22% less repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 313
24% less call options, than puts
Call options by funds: $202M | Put options by funds: $267M
44% less first-time investments, than exits
New positions opened: 83 | Existing positions closed: 149
Top Buyers
| 1 |
HI
HBK Investments
Dallas,
Texas
|
+$619M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$546M |
| 3 |
DKCM
Davidson Kempner Capital Management
New York
|
+$533M |
| 4 |
Barclays
London,
United Kingdom
|
+$497M |
| 5 |
Citigroup
New York
|
+$334M |
Top Sellers
| 1 |
ClearBridge Investments
New York
|
-$917M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$737M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$426M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$318M |
| 5 |
JP Morgan Chase
New York
|
-$317M |
ALXN Hedge Fund Activity: Q1 2021 in Review
752 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2021, worth a combined $31.3B — down 0.1% from $31.3B a quarter earlier.
Sellers outnumbered buyers: 149 funds closed out of ALXN and 83 opened new positions — a net loss of 66 holders — while 313 trimmed existing stakes and 244 added.
The largest buyer was HBK Investments, adding an estimated $619M. The largest seller was ClearBridge Investments, exiting entirely with an estimated $917M sold.
- 752 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2021, down from 824 in Q4 2020.
- Funds reported $31.3B of Alexion Pharmaceuticals stock for Q1 2021, down 0.1% quarter-over-quarter.
- 83 funds opened new Alexion Pharmaceuticals positions in Q1 2021 and 149 closed out, a net change of -66 holders.
- The largest Alexion Pharmaceuticals buyer in Q1 2021 was HBK Investments, an estimated $619M added.
- The largest Alexion Pharmaceuticals seller in Q1 2021 was ClearBridge Investments, an estimated $917M sold.
Based on aggregated 13F filings for Q1 2021.